SENATE BILL 723

J3 8lr2240 CF HB 343

By: Senators Klausmeier, Della, and Pugh

Introduced and read first time: February 1, 2008

Assigned to: Finance

Committee Report: Favorable with amendments

Senate action: Adopted

Read second time: March 24, 2008

CHAPTER ____

1 AN ACT concerning

5

7

8

9

17

2 Pharmacy Benefits Managers - Prescription Drug Substitution Therapeutic 3 **Interchanges**

4 FOR the purpose of prohibiting a pharmacy benefits manager from substituting one prescription drug for the drug originally prescribed or its agent from requesting 6 a therapeutic interchange unless certain conditions are met; requiring a pharmacy benefits manager to disclose certain information to a purchaser if a drug substitution is made; requiring a pharmacy benefits manager or its agent to obtain a certain authorization to make a drug substitution therapeutic 10 interchange and to make certain disclosures to a prescriber; providing for certain exceptions; prohibiting a pharmacy benefits manager from substituting 11 a drug for a currently prescribed drug unless the pharmacy benefits manager 12 provides a beneficiary or the beneficiary's representative with certain 13 information requiring a pharmacy benefits manager or its agent to disclose 14 15 certain information to a beneficiary and include a certain insert and a certain 16 telephone number with the prescription drug dispensed; requiring a pharmacy benefits manager or its agent to cancel and reverse a therapeutic interchange under certain circumstances; requiring a pharmacy benefits manager or its 18 19 agent to take certain actions if a therapeutic interchange is reversed; requiring 20 a pharmacy benefits manager to maintain a certain toll-free telephone number; requiring certain disclosures to comply with certain privacy standards; 21 22 requiring a pharmacy benefits manager to establish certain policies and 23 procedures; making certain provisions applicable to health maintenance 24 organizations; providing certain penalties; defining certain terms; and generally 25 relating to regulation of pharmacy benefits managers.

EXPLANATION: CAPITALS INDICATE MATTER ADDED TO EXISTING LAW.

[Brackets] indicate matter deleted from existing law.

Underlining indicates amendments to bill.

Strike out indicates matter stricken from the bill by amendment or deleted from the law by amendment.



1 2 3 4 5 6	BY adding to Article – Insurance Section 15–1601 <u>and 15–1602</u> to be under the new subtitle "Subtitle 16. Pharmacy Benefits Managers" Annotated Code of Maryland (2006 Replacement Volume and 2007 Supplement)
7	BY adding to
8	Article – Health – General
9	Section 19–706(ppp)
10	Annotated Code of Maryland
11	(2005 Replacement Volume and 2007 Supplement)
12 13	SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF MARYLAND, That the Laws of Maryland read as follows:
14	Article - Insurance
15	SUBTITLE 16. PHARMACY BENEFITS MANAGERS.
16	15-1601.
10	10-1001.
17	(A) (1) IN THIS SECTION THE FOLLOWING WORDS HAVE THE
18	MEANINGS INDICATED.
19	(2) "BENEFICIARY" MEANS AN INDIVIDUAL ON WHOSE BEHALF A
20	PURCHASER ENTERS INTO AN AGREEMENT WITH A PHARMACY BENEFITS
21	MANAGER.
22	(3) (1) "PHARMACY BENEFITS MANAGEMENT SERVICES"
23	(3) (1) "PHARMACY BENEFITS MANAGEMENT SERVICES" MEANS THE ADMINISTRATION OR MANAGEMENT OF PRESCRIPTION DRUG
$\frac{23}{24}$	BENEFITS.
05	
25 26	(H) "PHARMACY BENEFITS MANAGEMENT SERVICES"
26	INCLUDES:
27	1. PROCUREMENT OF PRESCRIPTION DRUGS AT A
28	NEGOTIATED RATE FOR DISPENSATION WITHIN THE STATE;
29	2. PROCESSING OF PRESCRIPTION DRUG CLAIMS;
30	3. ADMINISTRATION OF PAYMENTS RELATED TO
31	PRESCRIPTION DRUG CLAIMS; AND
00	
32 33	4. NEGOTIATING OR ENTERING INTO CONTRACTUAL
υŪ	ARRANGEMENTS WITH PHARMACY PROVIDERS.

1	(4) "Pharmacy benefits manager" means a person that
2	PERFORMS PHARMACY BENEFITS MANAGEMENT SERVICES.
3	(5) (I) "Purchaser" means a person that enters into an
4	AGREEMENT WITH A PHARMACY BENEFITS MANAGER FOR THE PROVISION OF
5	PHARMACY BENEFITS MANAGEMENT SERVICES.
6	(H) "PURCHASER" INCLUDES THE STATE.
7	(B) THE PROVISIONS OF THIS SECTION DO NOT APPLY TO A MANAGED
8	CARE ORGANIZATION AUTHORIZED BY TITLE 15, SUBTITLE 1 OF THE
9	HEALTH - GENERAL ARTICLE.
J	HUMBHI — QUAUNDANGHOBB.
10	(C) A PHARMACY BENEFITS MANAGER MAY NOT SUBSTITUTE ANOTHER
11	PRESCRIPTION DRUG FOR THE CURRENTLY PRESCRIBED PRESCRIPTION DRUG
12	UNLESS:
	<u></u>
13	(1) THE SUBSTITUTION IS MADE FOR MEDICAL REASONS THAT
14	BENEFIT THE BENEFICIARY; OR
15	(2) THE SUBSTITUTION RESULTS IN FINANCIAL SAVINGS AND
16	BENEFITS TO THE PURCHASER.
17	(D) IF A PRESCRIPTION DRUG SUBSTITUTION IS MADE UNDER THIS
18	SECTION, THE PHARMACY BENEFITS MANAGER SHALL DISCLOSE TO THE
19	PURCHASER ANY BENEFIT OR PAYMENT:
00	(4)
20	(1) RELATED TO THE SUBSTITUTION; AND
21	(2) RECEIVED IN ANY FORM BY THE PHARMACY BENEFITS
22	MANAGER FROM A PHARMACEUTICAL MANUFACTURER OR OTHER PERSON.
	WENT CHERT FROM A FIRMWING FOR WINNEY ACTORER OR OTHER FERSON.
23	(E) EXCEPT AS PROVIDED IN SUBSECTIONS (G) AND (H) OF THIS
24	SECTION, A PHARMACY BENEFITS MANAGER SHALL:
25	(1) OBTAIN AUTHORIZATION FROM A PRESCRIBER TO
26	SUBSTITUTE ANOTHER PRESCRIPTION DRUG FOR A CURRENTLY PRESCRIBED
27	PRESCRIPTION DRUG; AND
28	(2) DISCLOSE TO THE PRESCRIBER:
29	(I) THE COST SAVINGS FOR THE PURCHASER, IF ANY, THAT
30	RESULT FROM THE DRUG SUBSTITUTION;

1	(H) THE DIFFERENCE, IF ANY, IN COPAYMENTS OR OTHER
2	OUT-OF-POCKET COSTS PAID BY THE BENEFICIARY TO OBTAIN THE
3	SUBSTITUTE DRUG;
4	(HI) THE EXISTENCE OF ADDITIONAL PAYMENTS RECEIVED
5	BY THE PHARMACY BENEFITS MANAGER THAT ARE NOT REFLECTED IN THE
6	COST SAVINGS TO THE PURCHASER;
	COST SITURGE TO THE T CHOIMEDIN,
7	(IV) THE CIRCUMSTANCES, IF ANY, UNDER WHICH THE
8	CURRENTLY PRESCRIBED DRUG WILL BE COVERED;
9	(V) THE CIRCUMSTANCES, IF ANY, AND EXTENT TO WHICH
10	HEALTH CARE COSTS RELATED TO THE DRUG SUBSTITUTION WILL BE
11	COMPENSATED; AND
12	(VI) ANY KNOWN DIFFERENCES IN POTENTIAL EFFECTS ON A
13	BENEFICIARY'S HEALTH AND SAFETY, INCLUDING SIDE EFFECTS.
14	(F) IF AUTHORIZATION IS GIVEN VERBALLY, A PHARMACY BENEFITS
15	MANAGER SHALL RECORD THE NAME AND TITLE OF THE PRESCRIBER
16	AUTHORIZING THE PRESCRIPTION DRUG SUBSTITUTION.
17	(G) SUBSECTION (E) OF THIS SECTION DOES NOT APPLY IF THE
18	SUBSTITUTION IS FROM A BRAND NAME DRUG TO A GENERIC DRUG, AND THE
19	SUBSTITUTION IS MADE IN ACCORDANCE WITH § 12-504 OF THE HEALTH
20	OCCUPATIONS ARTICLE.
21	(H) SUBSECTION (E)(2) OF THIS SECTION DOES NOT APPLY IF:
22	(1) THE CURRENTLY PRESCRIBED DRUG IS NO LONGER
$\overline{23}$	AVAILABLE IN THE MARKET; OR
24	(2) THE SUBSTITUTION IS REQUIRED FOR COVERAGE REASONS
25	BECAUSE THE PRESCRIBED DRUG IS NOT COVERED BY THE BENEFICIARY'S
26	FORMULARY OR PLAN.
27	(I) A PHARMACY BENEFITS MANAGER MAY NOT SUBSTITUTE ANOTHER
28	PRESCRIPTION DRUG FOR A CURRENTLY PRESCRIBED PRESCRIPTION DRUG
29	UNLESS THE PHARMACY BENEFITS MANAGER PROVIDES THE BENEFICIARY OR
30	THE BENEFICIARY'S REPRESENTATIVE THE FOLLOWING:
91	
31 32	(1) UNLESS THE SUBSTITUTION WAS EXEMPTED UNDER
\mathfrak{I}	SUBSECTION (G) OF THIS SECTION, A NOTIFICATION THAT:

1	(I) THE PHARMACY BENEFITS MANAGER REQUESTED A
2	DRUG SUBSTITUTION BY CONTACTING THE BENEFICIARY'S PRESCRIBER; AND
3	(II) THE PRESCRIBER APPROVED THE DRUG SUBSTITUTION;
4	(2) THE NAMES OF THE PROPOSED DRUG SUBSTITUTION AND THE
5	CURRENTLY PRESCRIBED DRUG;
6	(3) THE DIFFERENCE, IF ANY, IN COPAYMENTS OR OTHER
7	OUT-OF-POCKET COSTS PAID BY THE BENEFICIARY TO OBTAIN THE
8	SUBSTITUTE DRUG;
9	(4) ANY KNOWN DIFFERENCES IN POTENTIAL EFFECTS ON A
10	BENEFICIARY'S HEALTH AND SAFETY, INCLUDING SIDE EFFECTS;
11	(5) THE CIRCUMSTANCES, IF ANY, UNDER WHICH THE
12	CURRENTLY PRESCRIBED DRUG WILL BE COVERED;
13	(6) THE CIRCUMSTANCES, IF ANY, AND THE EXTENT TO WHICH
14	HEALTH CARE COSTS RELATED TO THE DRUG SUBSTITUTION WILL BE
15	COMPENSATED;
16	(7) A NOTIFICATION THAT THE BENEFICIARY MAY DECLINE THE
17	DRUG SUBSTITUTION IF THE CURRENTLY PRESCRIBED DRUG REMAINS ON THE
18	BENEFICIARY'S FORMULARY, AND THE BENEFICIARY IS WILLING TO PAY ANY
19	DIFFERENCE IN THE COPAYMENT AMOUNT; AND
20	(8) A TOLL-FREE TELEPHONE NUMBER TO COMMUNICATE WITH
21	THE PHARMACY BENEFITS MANAGER.
22	(J) (1) A PHARMACY BENEFITS MANAGER SHALL CANCEL AND
23	REVERSE A PRESCRIPTION DRUG SUBSTITUTION ON WRITTEN OR VERBAL
24	INSTRUCTIONS FROM A PRESCRIBER, THE BENEFICIARY, OR THE
25	BENEFICIARY'S REPRESENTATIVE.
26	(2) IF A PRESCRIBER, THE BENEFICIARY, OR THE BENEFICIARY'S
27	REPRESENTATIVE CANCELS AND REVERSES A DRUG SUBSTITUTION, THE
28	PHARMACY BENEFITS MANAGER SHALL:
29	(I) OBTAIN A PRESCRIPTION FOR AND DISPENSE THE
30	CURRENTLY PRESCRIBED DRUG;
31	(II) CHARGE THE BENEFICIARY ONLY ONE COPAYMENT; AND

1	(HI) IF A BENEFICIARY WILL EXHAUST THE SUPPLY OF THE
2	CURRENTLY PRESCRIBED DRUG BEFORE A REPLACEMENT SHIPMENT WILL
3	ARRIVE TO THE BENEFICIARY, ARRANGE FOR DISPENSING OF AN APPROPRIATE
4	QUANTITY OF REPLACEMENT DRUGS AT A RETAIL OR INSTITUTIONAL
5	PHARMACY AT NO ADDITIONAL COST TO THE BENEFICIARY.
6	(3) A PHARMACY BENEFITS MANAGER MAY NOT BE REQUIRED TO
7	CANCEL AND REVERSE A DRUG SUBSTITUTION IF:
_	
8	(I) THE PRESCRIBED DRUG IS NO LONGER ON THE
9	PURCHASER'S FORMULARY; OR
10	(II) A BENEFICIARY IS UNWILLING TO PAY A HIGHER
11	COPAYMENT OR OTHER COST ASSOCIATED WITH THE PRESCRIBED DRUG.
11	COTATIVISME OR OTHER COST ASSOCIATED WITH THE TRESCRIBED DROOF
12	(K) A PHARMACY BENEFITS MANAGER SHALL MAINTAIN A TOLL-FREE
13	TELEPHONE NUMBER 24 HOURS A DAY, 7 DAYS A WEEK, FOR PRESCRIBERS,
14	PHARMACY PROVIDERS, AND BENEFICIARIES.
15	(L) ALL DISCLOSURES MADE UNDER THIS SECTION SHALL COMPLY
16	WITH THE PRIVACY STANDARDS OF THE FEDERAL HEALTH INSURANCE
17	PORTABILITY AND ACCOUNTABILITY ACT.
10	()
18	(M) ON OR BEFORE APRIL 1, 2009, THE COMMISSIONER SHALL ADOPT
19	REGULATIONS TO IMPLEMENT THIS SECTION.
20	(N) (1) THE COMMISSIONER MAY ASSESS A CIVIL PENALTY NOT
21	EXCEEDING \$10,000 FOR EACH VIOLATION OF THIS SECTION.
	EXCEPTING \$10,000 FOR EXCITATION OF THIS SECTION.
22	(2) In addition to or instead of assessing a civil penalty,
23	THE COMMISSIONER MAY REQUIRE THE PHARMACY BENEFITS MANAGER TO
24	MAKE RESTITUTION TO ANY PERSON WHO HAS SUFFERED FINANCIAL INJURY
25	BECAUSE OF THE VIOLATION OF THIS SECTION.
26	<u>15–1601.</u>
07	(·) T
27	(A) IN THIS SUBTITLE THE FOLLOWING WORDS HAVE THE MEANINGS
28	INDICATED.
29	(B) "AGENT" MEANS A PHARMACY, A PHARMACIST, A MAIL ORDER
30	PHARMACY, OR A NONRESIDENT PHARMACY ACTING ON BEHALF OR AT THE
31	DIRECTION OF A PHARMACY BENEFITS MANAGER.
J 1	DIMEDITOR OF A LIMINIAULI DEREFILD MANAGEM

32 (C) "BENEFICIARY" MEANS AN INDIVIDUAL WHO RECEIVES
33 PRESCRIPTION DRUG COVERAGE OR BENEFITS FROM A PURCHASER.

1	(D) "ERISA" HAS THE MEANING STATED IN § 8–301 OF THIS ARTICLE.
2	(E) "NONPROFIT HEALTH MAINTENANCE ORGANIZATION" HAS THE
3	MEANING STATED IN § 6–121(A) OF THIS ARTICLE.
4	(F) "NONRESIDENT PHARMACY" HAS THE MEANING STATED IN § 12–403
5	OF THE HEALTH OCCUPATIONS ARTICLE.
6	(G) "PHARMACIST" HAS THE MEANING STATED IN § 12-101 OF THE
7	HEALTH OCCUPATIONS ARTICLE.
0	
8 9	(H) "PHARMACY" HAS THE MEANING STATED IN § 12–101 OF THE
Э	HEALTH OCCUPATIONS ARTICLE.
10	(I) (1) "PHARMACY BENEFITS MANAGEMENT SERVICES" MEANS:
11	(I) THE PROCUREMENT OF PRESCRIPTION DRUGS AT A
12	NEGOTIATED RATE FOR DISPENSATION WITHIN THE STATE TO BENEFICIARIES;
13	(II) THE ADMINISTRATION OR MANAGEMENT OF
L4	PRESCRIPTION DRUG COVERAGE PROVIDED BY A PURCHASER FOR
15	BENEFICIARIES; AND
L6	(III) ANN OF THE POLLOWING SERVICES PROTECTED WITH
L7	(III) ANY OF THE FOLLOWING SERVICES PROVIDED WITH REGARD TO THE ADMINISTRATION OF PRESCRIPTION DRUG COVERAGE:
- •	TEGIND TO THE ADMINISTRATION OF TRESCRIPTION DICCO COVERAGE.
18	$\underline{1.}$ MAIL SERVICE PHARMACY;
	0
19 20	2. <u>CLAIMS PROCESSING, RETAIL NETWORK</u> MANAGEMENT, AND PAYMENT OF CLAIMS TO PHARMACIES FOR PRESCRIPTION
21	DRUGS DISPENSED TO BENEFICIARIES;
22	3. <u>CLINICAL FORMULARY DEVELOPMENT AND</u>
23	MANAGEMENT SERVICES;
24	4. REBATE CONTRACTING AND ADMINISTRATION;
	ii iiibiiii continuonii maniniiiiiiiiiiiiiiiiiiiiiiiiiiiiiii
25	5. PATIENT COMPLIANCE, THERAPEUTIC
26	INTERVENTION, AND GENERIC SUBSTITUTION PROGRAMS; OR
27	6. DISEASE MANAGEMENT PROGRAMS.
••	<u>o.</u> <u>Disease management frograms.</u>
28	(2) "PHARMACY BENEFITS MANAGEMENT SERVICES" DOES NOT

INCLUDE ANY SERVICE PROVIDED BY A NONPROFIT HEALTH MAINTENANCE

29

31

32

<u>(I)</u>

UTILIZATION REVIEW;

1	ORGANIZATION THAT OPERATES AS A GROUP MODEL, PROVIDED THAT THE
2	SERVICE:
3	(I) IS PROVIDED SOLELY TO A MEMBER OF THE NONPROFIT
4	HEALTH MAINTENANCE ORGANIZATION; AND
5	(II) IS FURNISHED THROUGH THE INTERNAL PHARMACY
6	OPERATIONS OF THE NONPROFIT HEALTH MAINTENANCE ORGANIZATION.
7	(J) "PHARMACY BENEFITS MANAGER" MEANS A PERSON THAT
8	PERFORMS PHARMACY BENEFITS MANAGEMENT SERVICES.
9	(K) "PHARMACY AND THERAPEUTICS COMMITTEE" MEANS A
10	COMMITTEE ESTABLISHED BY A PHARMACY BENEFITS MANAGER TO:
11	(1) OBJECTIVELY APPRAISE AND EVALUATE PRESCRIPTION
12	DRUGS; AND
13	(2) MAKE RECOMMENDATIONS TO A PURCHASER REGARDING THE
14	SELECTION OF DRUGS FOR THE PURCHASER'S FORMULARY.
	SELECTION OF BROOK FOR THE PONCHASER STORMORANT.
15	(L) (1) "PURCHASER" MEANS THE STATE EMPLOYEE AND RETIREE
16	HEALTH AND WELFARE BENEFITS PROGRAM, AN INSURER, A NONPROFIT
17	HEALTH SERVICE PLAN, OR A HEALTH MAINTENANCE ORGANIZATION THAT:
	III WILL SHAW TO I IMM OF THE WAR TO THE WAR
18	(I) PROVIDES PRESCRIPTION DRUG COVERAGE OR
19	BENEFITS IN THE STATE; AND
20	(II) ENTERS INTO AN AGREEMENT WITH A PHARMACY
21	BENEFITS MANAGER FOR THE PROVISION OF PHARMACY BENEFITS
22	MANAGEMENT SERVICES.
	MANAGEMENT SERVICES.
23	(2) "PURCHASER" DOES NOT INCLUDE A PERSON THAT PROVIDES
24	PRESCRIPTION DRUG COVERAGE OR BENEFITS THROUGH PLANS SUBJECT TO
25	ERISA AND DOES NOT PROVIDE PRESCRIPTION DRUG COVERAGE OR BENEFITS
26	THROUGH INSURANCE, UNLESS THE PERSON IS A MULTIPLE EMPLOYER
27	WELFARE ARRANGEMENT AS DEFINED IN § 514(B)(6)(A)(II) OF ERISA.
.	WELFARE ARRAINGEMENT AS DEFINED IN § 314(B)(U)(A)(II) OF EMISA.
28	(M) (1) "THERAPEUTIC INTERCHANGE" MEANS ANY CHANGE FROM
29	
J J	ONE PRESCRIPTION DRUG TO ANOTHER.
30	(2) "THERAPEUTIC INTERCHANGE" DOES NOT INCLUDE:
,0	(2) I HERAFEUTIC INTERCHANGE DUES NOT INCLUDE:

A CHANGE INITIATED PURSUANT TO A DRUG

1	(II) A CHANGE INITIATED FOR PATIENT SAFETY REASONS;
2	(III) A CHANGE REQUIRED DUE TO MARKET UNAVAILABILITY
3	OF THE CURRENTLY PRESCRIBED DRUG;
4	(IV) A CHANGE FROM A BRAND NAME DRUG TO A GENERIC
5	DRUG IN ACCORDANCE WITH § 12-504 OF THE HEALTH OCCUPATIONS
6	ARTICLE; OR
7	(V) A CHANGE REQUIRED FOR COVERAGE REASONS
8	BECAUSE THE ORIGINALLY PRESCRIBED DRUG IS NOT COVERED BY THE
9	BENEFICIARY'S FORMULARY OR PLAN.
10	(N) "THERAPEUTIC INTERCHANGE SOLICITATION" MEANS ANY
11	COMMUNICATION BY A PHARMACY BENEFITS MANAGER FOR THE PURPOSE OF
12	REQUESTING A THERAPEUTIC INTERCHANGE.
13	<u>15–1602.</u>
L 4	(A) A PHARMACY BENEFITS MANAGER OR ITS AGENT MAY NOT REQUEST
15	A THERAPEUTIC INTERCHANGE UNLESS:
l6 l7	(1) THE PROPOSED THERAPEUTIC INTERCHANGE IS FOR
L 1	MEDICAL REASONS THAT BENEFIT THE BENEFICIARY; OR
18	(2) THE PROPOSED THERAPEUTIC INTERCHANGE WILL RESULT IN
L9	FINANCIAL SAVINGS AND BENEFITS TO THE PURCHASER OR THE BENEFICIARY.
20	(B) (1) BEFORE MAKING A THERAPEUTIC INTERCHANGE, A
21	PHARMACY BENEFITS MANAGER OR ITS AGENT SHALL OBTAIN AUTHORIZATION
22	FROM A PRESCRIBER OR AN INDIVIDUAL AUTHORIZED BY THE PRESCRIBER.
23	(C) IN ANY THERAPEUTIC INTERCHANGE SOLICITATION, THE
24	FOLLOWING SHALL BE DISCLOSED TO THE PRESCRIBER:
25	(1) THE A THEO ADDITION OF THE POLICE OF THE
10	(1) THAT A THERAPEUTIC INTERCHANGE IS BEING SOLICITED;
26	(2) THE CIRCUMSTANCES UNDER WHICH THE ORIGINALLY
27	PRESCRIBED DRUG WILL BE COVERED BY THE PURCHASER;
28	(3) THE DIFFERENCE IN COPAYMENTS OR COINSURANCE TO BE
29	PAID BY THE BENEFICIARY TO OBTAIN THE PROPOSED DRUG;

1	(4) THE CIRCUMSTANCES AND EXTENT TO WHICH HEALTH CARE
2	COSTS RELATED TO THE THERAPEUTIC INTERCHANGE WILL BE COMPENSATED;
3	AND
4	(5) ANY CLINICALLY SIGNIFICANT DIFFERENCES, AS
5	DETERMINED BY A PHARMACY AND THERAPEUTICS COMMITTEE OF THE
6	PHARMACY BENEFITS MANAGER, WITH RESPECT TO EFFICACY, SIDE EFFECTS,
7	AND POTENTIAL IMPACT ON HEALTH AND SAFETY.
8	(D) WHEN COLICIPING A WHED A DELIVER OF INVESTIGATION OF EDOM A
9	(D) WHEN SOLICITING A THERAPEUTIC INTERCHANGE FROM A
	PRESCRIBER, A PHARMACY BENEFITS MANAGER OR ITS AGENT MAY NOT MAKE A
10	CLAIM THAT THE THERAPEUTIC INTERCHANGE WILL SAVE THE PURCHASER
11	MONEY UNLESS THE CLAIM CAN BE SUBSTANTIATED.
10	(-) T
12	(E) IF THE PHARMACY BENEFITS MANAGER OR ITS AGENT RECEIVES
13	PAYMENT FOR MAKING A THERAPEUTIC INTERCHANGE FROM A
14	PHARMACEUTICAL MANUFACTURER OR OTHER PERSON, INCLUDING THE
15	PHARMACY BENEFITS MANAGER, THAT IS NOT REFLECTED IN COST SAVINGS TO
16	THE PURCHASER, THE EXISTENCE OF THE PAYMENT SHALL BE COMMUNICATED
17	TO THE PRESCRIBER AT THE TIME OF THE THERAPEUTIC INTERCHANGE
18	SOLICITATION.
19	(F) IF A THERAPEUTIC INTERCHANGE OCCURS, THE PHARMACY
20	BENEFITS MANAGER OR ITS AGENT SHALL:
21	(1) DISCLOSE TO THE BENEFICIARY, ORALLY OR IN WRITING:
22	(I) THAT THE PHARMACY BENEFITS MANAGER OR ITS
23	AGENT REQUESTED A THERAPEUTIC INTERCHANGE BY CONTACTING THE
24	BENEFICIARY'S PRESCRIBER;
25	(II) THE PRESCRIBER APPROVED THE THERAPEUTIC
26	INTERCHANGE;
27	(III) THE NAMES OF THE ORIGINALLY PRESCRIBED DRUG
28	AND THE DRUG DISPENSED PURSUANT TO THE THERAPEUTIC INTERCHANGE;
	•
29	(IV) THE DIFFERENCE IN COPAYMENTS OR COINSURANCE TO
30	BE PAID BY THE BENEFICIARY TO OBTAIN THE DRUG DISPENSED PURSUANT TO
31	THE THERAPEUTIC INTERCHANGE;
32	(V) THE CIRCUMSTANCES UNDER WHICH THE ORIGINALLY
33	PRESCRIBED DRUG WILL BE COVERED;
	· · · · · · · · · · · · · · · · · · ·

1	(VI) THE CIRCUMSTANCES UNDER AND THE EXTENT TO
2	WHICH HEALTH CARE COSTS RELATED TO THE THERAPEUTIC INTERCHANGE
3	WILL BE COMPENSATED; AND
4	(VII) THAT THE BENEFICIARY MAY DECLINE THE
5	THERAPEUTIC INTERCHANGE IF THE ORIGINALLY PRESCRIBED DRUG REMAINS
6	ON THE BENEFICIARY'S FORMULARY, AND THE BENEFICIARY IS WILLING TO PAY
7	ANY DIFFERENCE IN THE COPAYMENT OR COINSURANCE; AND
8	(2) INCLUDE WITH THE PRESCRIPTION DRUG DISPENSED:
9 10	(I) A PATIENT PACKAGE INSERT ABOUT POTENTIAL SIDE EFFECTS; AND
11 12	(II) A TOLL-FREE TELEPHONE NUMBER TO COMMUNICATE WITH THE PHARMACY BENEFITS MANAGER.
13	(G) (1) A PHARMACY BENEFITS MANAGER OR ITS AGENT SHALL
14	CANCEL AND REVERSE A THERAPEUTIC INTERCHANGE ON WRITTEN OR VERBAL
15	INSTRUCTIONS FROM A PRESCRIBER, THE BENEFICIARY, OR THE
16	BENEFICIARY'S REPRESENTATIVE.
17	(2) IF A THERAPEUTIC INTERCHANGE IS REVERSED, THE
18	PHARMACY BENEFITS MANAGER OR ITS AGENT SHALL:
19	(I) OBTAIN A PRESCRIPTION FOR AND DISPENSE THE
20	ORIGINALLY PRESCRIBED PRESCRIPTION DRUG; AND
21 22	(II) CHARGE THE BENEFICIARY NO MORE THAN ONE
22	COPAYMENT.
23	(3) If the therapeutic interchange occurred through a
$\frac{24}{24}$	MAIL ORDER PHARMACY AND A BENEFICIARY WILL EXHAUST AN EXISTING
25	SUPPLY OF THE ORIGINALLY PRESCRIBED PRESCRIPTION DRUG BEFORE A
26	REPLACEMENT SHIPMENT WILL ARRIVE TO THE BENEFICIARY, THE PHARMACY
27	BENEFITS MANAGER OR ITS AGENT SHALL ARRANGE FOR DISPENSING OF AN
28	APPROPRIATE QUANTITY OF REPLACEMENT PRESCRIPTION DRUGS AT A LOCAL
29	COMMUNITY PHARMACY AT NO ADDITIONAL COST TO THE BENEFICIARY.
30	(4) A PHARMACY BENEFITS MANAGER OR ITS AGENT MAY NOT BE
31	REQUIRED TO CANCEL AND REVERSE A THERAPEUTIC INTERCHANGE IF A
32	BENEFICIARY IS UNWILLING TO PAY A HIGHER COPAYMENT OR COINSURANCE
33	ASSOCIATED WITH THE ORIGINALLY PRESCRIBED PRESCRIPTION DRUG.

ASSOCIATED WITH THE ORIGINALLY PRESCRIBED PRESCRIPTION DRUG.

$1\\2$	(H) (1) A PHARMACY BENEFITS MANAGER SHALL MAINTAIN A TOLL-FREE TELEPHONE NUMBER MONDAY THROUGH SATURDAY FOR
3	PRESCRIBERS, PHARMACIES, PHARMACISTS, AND BENEFICIARIES TO REQUEST
4	INFORMATION REGARDING A THERAPEUTIC INTERCHANGE.
5	(2) THE TOLL-FREE TELEPHONE NUMBER SHALL BE ACCESSIBLE
6	FROM 8 A.M. UNTIL AT LEAST 8 P.M. EASTERN STANDARD TIME.
7	(I) ALL DISCLOSURES MADE UNDER THIS SECTION SHALL COMPLY
8	WITH THE PRIVACY STANDARDS SET FORTH IN STATE AND FEDERAL LAW.
	WITH THE THEFT STREET STREET STREET
9	(J) A PHARMACY BENEFITS MANAGER SHALL ESTABLISH APPROPRIATE
10	POLICIES AND PROCEDURES TO IMPLEMENT THE REQUIREMENTS OF THIS
11	SECTION.
12	(K) (1) THE COMMISSIONER MAY ASSESS A CIVIL PENALTY NOT
13	EXCEEDING \$10,000 FOR EACH VIOLATION OF THIS SECTION.
10	EXCEPTION OF THIS SECTION.
14	(2) IN ADDITION TO OR INSTEAD OF ASSESSING A CIVIL PENALTY.
15	THE COMMISSIONER MAY REQUIRE THE PHARMACY BENEFITS MANAGER TO
16	MAKE RESTITUTION TO ANY PERSON THAT HAS SUFFERED FINANCIAL INJURY
17	BECAUSE OF A VIOLATION OF THIS SECTION.
18	<u> Article - Health - General</u>
19	<u>19–706.</u>
20	(PPP) THE PROVISIONS OF TITLE 15, SUBTITLE 16 OF THE INSURANCE
21	ARTICLE APPLY TO HEALTH MAINTENANCE ORGANIZATIONS.
22 23	SECTION 2. AND BE IT FURTHER ENACTED, That this Act shall take effect
<i>2</i> 3	October 1, 2008.
	A 1
	Approved:
	Governor.
	President of the Senate.
	rresident of the Senate.
	Speaker of the House of Delegates.
	speaker of the House of Delegates.